{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:20Z","timestamp":1787027780564,"version":"build-2736575974"},"reference-count":258,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Analytics and Devices Ltd.","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the increasingly high medical and socioeconomic burden of NAFLD, the lack of approved pharmacotherapy regimens remains an unsolved issue. In this paper, we aimed to provide an update on the rapidly changing therapeutic landscape and highlight the major novel approaches to the treatment of this disease. In addition to describing the biomolecules and pathways identified as upcoming pharmacological targets for NAFLD, we reviewed the current status of drug discovery and development pipeline with a special focus on recent evidence from clinical trials.<\/jats:p>","DOI":"10.3390\/biomedicines10020274","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:02:53Z","timestamp":1643194973000},"page":"274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4690-1811","authenticated-orcid":false,"given":"Veronika A.","family":"Prikhodko","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Saint Petersburg State Chemical and Pharmaceutical University, 14A Prof. Popov Str., 197022 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia N.","family":"Bezborodkina","sequence":"additional","affiliation":[{"name":"Zoological Institute, Russian Academy of Sciences, 1 Universitetskaya emb., 199034 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-5531","authenticated-orcid":false,"given":"Sergey V.","family":"Okovityi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Saint Petersburg State Chemical and Pharmaceutical University, 14A Prof. Popov Str., 197022 St. Petersburg, Russia"},{"name":"Scientific, Clinical and Educational Center of Gastroenterology and Hepatology, Saint Petersburg State University, 7\/9 Universitetskaya emb., 199034 St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_2","first-page":"25","article-title":"Systematic review of existing guidelines for NAFLD assessment","volume":"7","author":"Monelli","year":"2021","journal-title":"Hepatoma Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving Role for Pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14656566.2021.1912014","article-title":"What considerations are there for the pharmacotherapeutic management of nonalcoholic steatohepatitis?","volume":"22","author":"Yoneda","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrendo.2014.143","article-title":"Thyroid hormone receptors and resistance to thyroid hormone disorders","volume":"10","author":"Sidhaye","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bbadis.2010.12.019","article-title":"Role of thyroid receptor \u03b2 in lipid metabolism","volume":"1812","author":"Pramfalk","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1194\/jlr.C088955","article-title":"Hepatic thyroid hormone receptor \u03b21 agonism: Good for lipids, good for bile?","volume":"59","author":"Dawson","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3389\/fendo.2019.00532","article-title":"The Role of Thyroid Hormones in Hepatocyte Proliferation and Liver Cancer","volume":"10","author":"Gionfra","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/S0618-8278(19)30266-X","article-title":"VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial","volume":"70","author":"Loomba","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_13","unstructured":"Li, X., He, H., Sho, E., Yang, B., and Wu, J.J. (2021, January 23\u201326). Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR-\u03b2 Agonist, in High Fat Diet Induced NASH SD Rats. Proceedings of the Digital International Liver Congress 2021, Virtual."},{"key":"ref_14","unstructured":"Wu, J., He, H., Palmer, M., and Yan, Y. (2021, January 12\u201315). A Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Asc41, A THR-\u0392 Agonist, for 28-Days in Overweight and Obese Subjects with Elevated LDL-C, a Population Characteristic of NAFLD. Proceedings of the Liver Meeting 2021, Virtual."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kirschberg, T., Jones, C., Xu, Y., Wang, Y., Fenaux, M., and Klucher, K. (2020, January 27\u201329). TERN-501, a Potent and Selective Agonist of Thyroid Hormone Receptor Beta, Strongly Reduces Histological Features and Biomarkers of Non-Alcoholic Steatohepatitis Associated Pathology in Rodent Models. Proceedings of the Digital International Liver Congress 2020, Virtual.","DOI":"10.1016\/S0168-8278(20)31829-8"},{"key":"ref_16","unstructured":"(2021, December 10). Ascletis Pharma Inc.. Available online: https:\/\/ascletis.com\/."},{"key":"ref_17","unstructured":"(2021, December 10). Terns Pharmaceuticals. Available online: https:\/\/www.ternspharma.com\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1194\/jlr.M020156","article-title":"The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2","volume":"53","author":"Qi","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14542","DOI":"10.14814\/phy2.14542","article-title":"Diacylglycerol acyltransferase 1\/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice","volume":"8","author":"Takemoto","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"166133","DOI":"10.1016\/j.bbadis.2021.166133","article-title":"FXR in liver physiology: Multiple faces to regulate liver metabolism","volume":"1867","author":"Panzitt","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.31000","article-title":"Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males with Metabolic Abnormalities","volume":"72","author":"Parks","year":"2020","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Loomba, R., Rinella, M., Harrison, S.A., Wong, V.W.-S., Ratziu, V., Mohseni, R., Lucas, J., Gutierrez, J.A., Rahimi, R., and Trotter, J. (2020, January 27\u201329). Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH. Proceedings of the Digital International Liver Congress 2020, Virtual.","DOI":"10.1016\/S0168-8278(20)30653-X"},{"key":"ref_27","unstructured":"(2021, December 10). Forma Therapeutics. Available online: https:\/\/www.formatherapeutics.com\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.jhepr.2021.100237","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.arcmed.2010.09.001","article-title":"Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic","volume":"41","author":"Gonen","year":"2010","journal-title":"Arch. Med. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/S0168-8278(20)31392-1","article-title":"Co-administration of PF-05221304 and PF-06865571 delivers robust whole liver fat reduction and mitigation of acetyl-coa carboxilase inhibitor induced hypertriglyceridemia in patients with NAFLD","volume":"73","author":"Calle","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: A multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_33","unstructured":"(2021, December 10). Sinew Pharma Inc.. Available online: https:\/\/www.sinewpharma.com\/en\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI25256","article-title":"Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation","volume":"115","author":"Dentin","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1505S","DOI":"10.1093\/ajcn\/83.6.1505S","article-title":"n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases","volume":"83","author":"Calder","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/B978-0-12-416003-3.00013-5","article-title":"Health benefits of n-3 polyunsaturated fatty acids: Eicosapentaenoic acid and docosahexaenoic acid","volume":"65","author":"Siriwardhana","year":"2012","journal-title":"Adv. Food Nutr. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.clnu.2017.08.031","article-title":"Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH-Proteomic and lipidomic insight","volume":"37","author":"Okada","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clnu.2015.05.001","article-title":"Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial","volume":"35","author":"Nogueira","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/adc.2010.192401","article-title":"Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial","volume":"96","author":"Nobili","year":"2011","journal-title":"Arch. Dis. Child."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"He, X.X., Wu, X.L., Chen, R.P., Chen, C., Liu, X.G., Wu, B.J., and Huang, Z.M. (2016). Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162368"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e12271","DOI":"10.1097\/MD.0000000000012271","article-title":"Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"97","author":"Yan","year":"2018","journal-title":"Medicine"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lee, C.H., Fu, Y., Yang, S.J., and Chi, C.C. (2020). Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients, 12.","DOI":"10.3390\/nu12092769"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e016334","DOI":"10.1161\/JAHA.119.016334","article-title":"Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers","volume":"9","author":"Climax","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_45","unstructured":"(2021, December 10). Affimune. Available online: https:\/\/www.afimmune.com\/."},{"key":"ref_46","first-page":"S294","article-title":"Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: Interim analysis results of the ICONA trial","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): Structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_48","unstructured":"(2021, December 10). Intercept Pharmaceuticals. Available online: https:\/\/www.interceptpharma.com\/homepage-non-usa\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.11648\/j.ijg.20190301.12","article-title":"Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis","volume":"3","author":"Chau","year":"2019","journal-title":"Int. J. Gastroenterol."},{"key":"ref_54","unstructured":"Enanta Pharmaceuticals, Inc. (2021, December 10). Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis: News Release; 2020. Available online: https:\/\/www.enanta.com\/investors\/news-releases\/press-release\/2020\/Enanta-Announces-Results-of-INTREPID-Study-of-EDP-305-for-the-Treatment-of-Primary-Biliary-Cholangitis\/default.aspx."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.livres.2021.08.003","article-title":"Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease","volume":"5","author":"Biagioli","year":"2021","journal-title":"Liver Res."},{"key":"ref_56","unstructured":"Enanta Pharmaceuticals, Inc. (2021, December 10). Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs: News Release; 2021. Available online: https:\/\/www.enanta.com\/investors\/news-releases\/press-release\/2021\/Enanta-Pharmaceuticals-Provides-Update-on-NASH-FXR-Agonist-Programs\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","article-title":"INT-767 improves histopathological features in a diet-induced ob\/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis","volume":"24","author":"Roth","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","article-title":"FXR agonists for NASH: How are they different and what difference do they make?","volume":"75","author":"Kremoser","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/164_2019_228","article-title":"Pharmacologic Modulation of Bile Acid-FXR-FGF15\/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis","volume":"256","author":"Schumacher","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.dld.2019.12.129","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results","volume":"52","author":"Lucas","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_63","unstructured":"Novartis (2021, December 10). A Randomized, Double-Blind, Placebo Controlled, 3-Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients with Non-Alcoholic Steatohepatitis (NASH): FLIGHT-FXR, 2020. Available online: https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=17816."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_65","unstructured":"Harrison, S.A., Ratziu, V., White, A., Reiss, G.M., Bowman, W.K., Gunn, N., Loustaud Ratti, V., Bureau, C., Lawitz, E.J., and Alkhouri, N. (2021, January 12\u201315). Vonafexor, s FXR Agonist, Induced Hepatic snd Renal Improvement in the Randomized, Double-Blind, Placebocontrolled LIVIFYNASH Trial. Proceedings of the Liver Meeting 2021, Virtual."},{"key":"ref_66","unstructured":"Novartis (2021, December 10). A randomized, Patient and Investigator Blinded, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients with Non-Alcoholic Steatohepatitis (NASH), 2020. Available online: https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=17527."},{"key":"ref_67","first-page":"97A","article-title":"Liver-Distributed FXR Agonist TERN-101 Demonstrates Favorable Safety and Efficacy Profile in NASH Phase 2a LIFT Study","volume":"74","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_68","unstructured":"(2021, December 10). Hepagene Therapeutics, Inc.. Available online: http:\/\/www.hepagene.com\/#\/m_about2."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"601349","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 from Mice to Human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_70","first-page":"5A","article-title":"Topline Results from the ALPINE 2\/3 Study: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b Trial Evaluating 3 Doses of the FGF19 Analogue Aldafermin on Liver Histology in Patients with Nonalcoholic Steatohepatitis and Stage 2 or 3 Fibrosis","volume":"74","author":"Harrison","year":"2021","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1210\/jendso\/bvab048.010","article-title":"BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b\/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH","volume":"5","author":"Frias","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"ref_73","unstructured":"(2021, December 10). Novo Nordisk. Available online: https:\/\/www.novonordisk.com\/."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klotho\u03b2 complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_76","unstructured":"Abdelmalek, M.F., Sanyal, A.J., Nakajima, A., Neuschwander-Tetri, B.A., Goodman, Z., Lawitz, E.J., Harrison, S.A., Jacobson, I.M., Imajo, K., and Gunn, N. (2021, January 12\u201315). Efficacy and Safety of Pegbelfermin in Patients with Nonalcoholic Steatohepatitis and Compensated Cirrhosis: Results from the Phase 2b, Randomized, Double-Blind, Placebo-Controlled Falcon 2 Study. Proceedings of the Liver Meeting 2021, Virtual."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10735-020-09898-1","article-title":"The roles of galectins in hepatic diseases","volume":"51","author":"Sun","year":"2020","journal-title":"J. Mol. Histol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"744518","DOI":"10.3389\/fmed.2021.744518","article-title":"Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis","volume":"8","author":"An","year":"2021","journal-title":"Front. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Traber, P.G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M.I., and Friedman, S.L. (2013). Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075361"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis with Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Hsieh, Y.C., Lee, K.C., Wu, P.S., Huo, T.I., Huang, Y.H., Hou, M.C., and Lin, H.C. (2021). Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. Cells, 10.","DOI":"10.3390\/cells10061562"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fphys.2012.00138","article-title":"Toll-like receptors in liver fibrosis: Cellular crosstalk and mechanisms","volume":"3","author":"Yang","year":"2012","journal-title":"Front. Physiol."},{"key":"ref_83","unstructured":"Huang, K.C., Chen, M.Y., Lin, C.L., Yang, S.S., Hsu, C.W., Wang, C.C., Huang, Y.H., Chang, C.C., Shih, Y.C., and Liu, S.H. (2020, January 27\u201329). JKB-111 in Patients with Non-Alcoholic Fatty Liver: A Phase 2 Randomized Double-Blind Placebo-Control Study. Proceedings of the Digital International Liver Congress 2020, Virtual."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fimmu.2020.00480","article-title":"LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis","volume":"11","author":"Klepfish","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.31236","article-title":"Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis","volume":"72","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jcmm.14074","article-title":"The lysyl oxidase like 2\/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis","volume":"23","author":"Schilter","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_88","unstructured":"(2021, December 10). Galecto, Inc.. Available online: https:\/\/galecto.com\/."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-020-00367-5","article-title":"Role of lysophosphatidic acid and its receptors in health and disease: Novel therapeutic strategies","volume":"6","author":"Geraldo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.116.237156","article-title":"Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis","volume":"360","author":"Bain","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_91","unstructured":"(2021, December 10). TaiwanJ Pharmaceuticals. Available online: https:\/\/www.taiwanj.com\/pages\/page_index_en."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Boeckmans, J., Natale, A., Rombaut, M., Buyl, K., Rogiers, V., De Kock, J., Vanhaecke, T., and Rodrigues, R.M. (2019). Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 9.","DOI":"10.3390\/cells9010037"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: A randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Colina","year":"2008","journal-title":"Dig. Liver Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jgh3.12650","article-title":"Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score","volume":"5","author":"Hatanaka","year":"2021","journal-title":"JGH Open"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.04.051","article-title":"Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome","volume":"662","author":"Sasaki","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3346\/jkms.2017.32.1.60","article-title":"Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness","volume":"32","author":"Lee","year":"2017","journal-title":"J. Korean Med. Sci."},{"key":"ref_101","first-page":"37","article-title":"Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet","volume":"5","author":"Nakagami","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPAR\u03b2\/\u03b4 and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_103","unstructured":"CymaBay Therapeutics (2021, December 10). CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis; 2019. Available online: https:\/\/www.globenewswire.com\/news-release\/2019\/06\/11\/1866763\/0\/en\/CymaBay-Therapeutics-Reports-Topline-12-Week-Data-from-an-Ongoing-Phase-2b-Study-of-Seladelpar-in-Patients-with-Nonalcoholic-Steatohepatitis.html."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jbmr.2364","article-title":"An insulin-sensitizing thiazolidinedione, which minimally activates PPAR\u03b3, does not cause bone loss","volume":"30","author":"Fukunaga","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/hep4.1723","article-title":"Deuterium-Stabilized (R)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPAR\u03b3 Activity","volume":"5","author":"Jacques","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eabf1948","DOI":"10.1126\/sciadv.abf1948","article-title":"GIP mediates the incretin effect and glucose tolerance by dual actions on \u03b1 cells and \u03b2 cells","volume":"7","author":"El","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00125-011-2317-z","article-title":"Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial","volume":"54","author":"Samson","year":"2011","journal-title":"Diabetologia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"541","DOI":"10.21037\/hbsn-21-231","article-title":"Semaglutide for nonalcoholic steatohepatitis: Closer to a solution?","volume":"10","author":"Liava","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4254\/wjh.v12.i8.493","article-title":"Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update","volume":"12","author":"Sofogianni","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: A post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_119","unstructured":"Koutsovasilis, A., Sotiropoulos, A., Pappa, M., Apostolou, O., Binikos, I., Kordinas, V., Papadaki, D., Tamvakos, I., and Bousboulas, S. (2016, January 14). Effectiveness of lixisenatide in nonalcoholic fatty liver disease in patients with type 2 diabetes after an acute coronary syndrome compared to sitagliptin and pioglitazone. Proceedings of the EASD Virtual Meeting 2016, Munich, Germany."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","article-title":"A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"170208","DOI":"10.1016\/j.peptides.2019.170208","article-title":"The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"125","author":"Thondam","year":"2020","journal-title":"Peptides"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Gastaldelli, A., Cusi, K., Land\u00f3, F., Bray, R., Brouwers, B., and Rodr\u00edguez, \u00c1. (2021, January 30). Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI). Proceedings of the EASD Virtual Meeting 2021, Virtual.","DOI":"10.1016\/S2213-8587(22)00070-5"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin","volume":"3","author":"Pocai","year":"2013","journal-title":"Mol. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults with Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_128","unstructured":"Jung, S.Y., Park, Y.J., Lee, J.S., Kim, E.J., Lee, Y.M., Kim, Y.H., Trautmann, M., and Kwon, S.C. (2016, January 10\u201314). Potent Cholesterol Lowering Effect by HM12525A, A Novel Long-acting GLP-1\/Glucagon Dual Receptor Agonist. Proceedings of the American Diabetes Association\u2019s (ADA) 76th Scientific Sessions, New Orleans, LA, USA."},{"key":"ref_129","unstructured":"(2021, December 10). Pfizer Inc.. Available online: https:\/\/www.pfizer.com\/."},{"key":"ref_130","unstructured":"Hanmi Pharmaceutical Co., Ltd. (2021, December 10). Available online: http:\/\/www.hanmipharm.com\/ehanmi\/handler\/Home-Start."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1804-P","DOI":"10.2337\/db20-1804-P","article-title":"HM15211, a Novel Long-Acting GLP-1\/GIP\/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN\/TAA\u2013Induced Liver Inflammation and Fibrosis Mice","volume":"69","author":"Kim","year":"2020","journal-title":"Diabetes"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/apt.12092","article-title":"Review article: A comparison of glucagon-like peptides 1 and 2","volume":"37","author":"Janssen","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.11569\/wcjd.v24.i7.1009","article-title":"Therapeutic effect of teduglutide on non-alcoholic fatty liver disease in rats","volume":"24","author":"Hu","year":"2016","journal-title":"World Chin. J. Dig."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/HMER.S158053","article-title":"Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: A 1-year randomized control trial","volume":"10","author":"Alam","year":"2018","journal-title":"Hepat. Med."},{"key":"ref_135","first-page":"491","article-title":"The efficacy and safety of vildagliptin treatment for nonalcoholic fatty liver disease in type 2 diabetes mellitus","volume":"42","author":"Ozan","year":"2020","journal-title":"Cumhur. Med. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/1806-9282.65.1.33","article-title":"The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: Preliminary data","volume":"65","author":"Li","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13098-021-00644-5","article-title":"Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"13","author":"Hattori","year":"2021","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1029-P","DOI":"10.2337\/db19-1029-P","article-title":"Teneligliptin Significantly Reduces Liver Fat Content (LFC) and Delays Progression of NASH in Type 2 Diabetes Mellitus Patients","volume":"68","author":"Gupta","year":"2019","journal-title":"Diabetes"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/br.2016.569","article-title":"Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes","volume":"4","author":"Mashitani","year":"2016","journal-title":"Biomed. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e101120187811","DOI":"10.2174\/1573399816999201110195634","article-title":"Dipeptidyl Peptidase IV Inhibitors for Nonalcoholic Fatty Liver Disease\u2014Systematic Review and Metanalysis","volume":"17","author":"Duarte","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4196\/kjpp.2019.23.6.459","article-title":"Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: A comparative study","volume":"23","author":"Wang","year":"2019","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_142","unstructured":"Sakai, Y., Nagashimada, M., Nagata, N., Ni, Y., Kaneko, S., and Ota, T. (2015, January 15). Dipeptidyl peptidase-4 inhibitor anagliptin alleviates lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice. Proceedings of the EASD Virtual Meeting 2015, Stockholm, Sweden."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","article-title":"Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects","volume":"10","author":"Kawakubo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e22696","DOI":"10.1002\/jbt.22696","article-title":"The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice","volume":"35","author":"Wang","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1139\/cjpp-2016-0026","article-title":"Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice","volume":"95","author":"Choi","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00795-013-0053-9","article-title":"Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis","volume":"47","author":"Klein","year":"2014","journal-title":"Med. Mol. Morphol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Saisho, Y. (2020). SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?. Diseases, 8.","DOI":"10.3390\/diseases8020014"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/a-0958-2441","article-title":"Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes","volume":"51","author":"Wu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"17","DOI":"10.36502\/2020\/droa.6159","article-title":"Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease","volume":"2","author":"Sumida","year":"2020","journal-title":"Diabetes Res. Open Access"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"100028","DOI":"10.1016\/j.metop.2020.100028","article-title":"Treatment of nonalcoholic fatty liver disease with dapagliflozin in non-diabetic patients","volume":"5","year":"2020","journal-title":"Metabol. Open"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/osp4.294","article-title":"Efficacy of canagliflozin against nonalcoholic fatty liver disease: A prospective cohort study","volume":"4","author":"Itani","year":"2018","journal-title":"Obes. Sci. Pract."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.24075\/brsmu.2020.034","article-title":"Effects of Empagliflozin and L-Ornithine L-Aspartate on Behavior, Cognitive Functions, and Physical Performance in Mice with Experimentally Induced Steatohepatitis","volume":"3","author":"Prikhodko","year":"2020","journal-title":"Bull. RSMU"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., and Kubotsu, Y. (Hepatol. Commun., 2021). Ipragliflozin Improves the Hepatic Outcomes of Patients with Diabetes with NAFLD, Hepatol. Commun., online ahead of print.","DOI":"10.1002\/hep4.1696"},{"key":"ref_155","first-page":"548A","article-title":"Remogliflozin Etabonate Reduces FIB-4 and NAFLD Fibrosis Scores in Type 2 Diabetic Subjects","volume":"64","author":"Wilkison","year":"2016","journal-title":"Hepatology"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s13300-020-00867-1","article-title":"Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials","volume":"11","author":"Gallo","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/dom.13654","article-title":"The effects of licogliflozin, a dual SGLT1\/2 inhibitor, on body weight in obese patients with or without diabetes","volume":"21","author":"He","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_161","unstructured":"Harrison, S.A., Manghi, F.P., Smith, W.B., Alpenidze, D., Aizenberg, D., Burggraaf, K., Chen, C.-Y., Zuckerman, E., Ravussin, E., and Charatcharoenwitthaya, P. (2019, January 8\u201312). LIK066 (Licogliflozin), an SGLT1\/2 Inhibitor, Robustly Decreases ALT and Improves Markers of Hepatic and Metabolic Health in Patients with Non-Alcoholic Fatty Liver Disease: Interim Analysis of a 12-Week, Randomized, Placebo-Controlled, Phase 2a Study. Proceedings of the Liver Meeting 2019, Boston, MA, USA."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jphs.2021.07.002","article-title":"Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice","volume":"147","author":"Honda","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s42000-018-0021-9","article-title":"The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)","volume":"17","author":"Tsochatzis","year":"2018","journal-title":"Hormones"},{"key":"ref_164","first-page":"186","article-title":"A Comparison of Ezetimibe and Acarbose in Decreasing Liver Transaminase in Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial","volume":"18","author":"Hajiaghamohammadi","year":"2013","journal-title":"Govaresh"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/hepr.13223","article-title":"Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients","volume":"48","author":"Komatsu","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Kim, J.W., Lee, Y.J., You, Y.H., Moon, M.K., Yoon, K.H., Ahn, Y.B., and Ko, S.H. (J. Cell. Biochem., 2018). Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and \u03b1-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes, J. Cell. Biochem., online ahead of print.","DOI":"10.1002\/jcb.28141"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Meroni, M., Longo, M., and Dongiovanni, P. (2019). The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients, 11.","DOI":"10.3390\/nu11112642"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"J. Dairy Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep4.1325","article-title":"Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients with Cirrhosis: A Randomized Trial","volume":"3","author":"Nieto","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.3748\/wjg.v19.i40.6911","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis","volume":"19","author":"Ma","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/hepr.12671","article-title":"Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials","volume":"46","author":"Gao","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_176","first-page":"921","article-title":"Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease","volume":"24","author":"Liu","year":"2016","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/S0168-8278(20)31389-1","article-title":"Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet","volume":"73","author":"Yamauchi","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_178","first-page":"101","article-title":"Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals","volume":"7","year":"2017","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1039\/C4FO00549J","article-title":"Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease","volume":"5","author":"Li","year":"2014","journal-title":"Food Funct."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.5114\/aoms.2019.86611","article-title":"Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease","volume":"15","author":"Yao","year":"2019","journal-title":"Arch. Med. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1007\/s00253-014-5752-1","article-title":"Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice","volume":"98","author":"Xin","year":"2014","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"25881","DOI":"10.3390\/ijms161025881","article-title":"Heat Killed Lactobacillus reuteri GMNL-263 Reduces Fibrosis Effects on the Liver and Heart in High Fat Diet-Hamsters via TGF-\u03b2 Suppression","volume":"16","author":"Ting","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_183","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann. Hepatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2011.02.020","article-title":"Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome","volume":"55","author":"Ezquer","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Hsu, M.J., Karkossa, I., Sch\u00e4fer, I., Christ, M., K\u00fchne, H., Schubert, K., Rolle-Kampczyk, U.E., Kalkhof, S., Nickel, S., and Seibel, P. (2020). Mitochondrial Transfer by Human Mesenchymal Stromal Cells Ameliorates Hepatocyte Lipid Load in a Mouse Model of NASH. Biomedicines, 8.","DOI":"10.3390\/biomedicines8090350"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.intimp.2016.11.012","article-title":"Compact bone-derived mesenchymal stem cells attenuate nonalcoholic steatohepatitis in a mouse model by modulation of CD4 cells differentiation","volume":"42","author":"Wang","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"18594","DOI":"10.18632\/oncotarget.23603","article-title":"Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4\/Sox2\/Klf4\/Parp1","volume":"9","author":"Chien","year":"2018","journal-title":"Oncotarget"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Overi, D., Carpino, G., Franchitto, A., Onori, P., and Gaudio, E. (2020). Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells, 9.","DOI":"10.3390\/cells9030590"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"100291","DOI":"10.1016\/j.jhepr.2021.100291","article-title":"A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation","volume":"3","author":"Nevens","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Iqbal, U., Perumpail, B.J., John, N., Sallam, S., Shah, N.D., Kwong, W., Cholankeril, G., Kim, D., and Ahmed, A. (2018). Judicious Use of Lipid Lowering Agents in the Management of NAFLD. Diseases, 6.","DOI":"10.3390\/diseases6040087"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Oniciu, D.C., Hashiguchi, T., Shibazaki, Y., and Bisgaier, C.L. (2018). Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM\u2122 model of NASH. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194568"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.crphar.2021.100051","article-title":"ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score","volume":"2","author":"Sanjay","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2014.8334","article-title":"Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial","volume":"312","author":"Stanley","year":"2014","journal-title":"JAMA"},{"key":"ref_197","unstructured":"(2021, December 10). Theratechnologies Inc.. Available online: https:\/\/www.theratech.com\/."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"3593951","DOI":"10.1155\/2016\/3593951","article-title":"The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis","volume":"2016","author":"Wei","year":"2016","journal-title":"Evid.-Based Complementary Altern. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.apsb.2012.06.003","article-title":"Effects and mechanisms of berberine in diabetes treatment","volume":"2","author":"Yin","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/bcp.14311","article-title":"Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials","volume":"86","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_201","first-page":"696","article-title":"Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials","volume":"29","author":"Zhang","year":"2020","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_203","unstructured":"Kowdley, K.V., Butler, P., Cubberley, S., Hand, A.L., Jenders, R.A., Kroon, J., Leibowitz, M., Moore, A.C., and Guyer, B. (2021, January 12\u201315). Miricorilant, a Selective GR Modulator, Induced a Rapid and Significant Reduction in Liver Fat Content in a Randomized, Placebo-Controlled Phase 2a Study in Patients with Non-Alcoholic Steatohepatitis. Proceedings of the Liver Meeting 2021, Virtual."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Li, F., Jiang, M., Ma, M., Chen, X., Zhang, Y., Zhang, Y., Yu, Y., Cui, Y., Chen, J., and Zhao, H. Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice. Acta Pharm. Sin. B 2021, in press, corrected proof.","DOI":"10.1016\/j.apsb.2021.09.009"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0168-8278(18)30928-0","article-title":"Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model","volume":"68","author":"Walczak","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jhbp.947","article-title":"Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial","volume":"28","author":"Glal","year":"2021","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Flores-Contreras, L., Sandoval-Rodr\u00edguez, A.S., Mena-Enriquez, M.G., Lucano-Landeros, S., Arellano-Olivera, I., Alvarez-\u00c1lvarez, A., Sanchez-Parada, M.G., and Armend\u00e1riz-Borunda, J. (2014). Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-131"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Cui, Y., Zhang, M., Leng, C., Blokzijl, T., Jansen, B.H., Dijkstra, G., and Faber, K.N. (2020). Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts. Cells, 9.","DOI":"10.3390\/cells9030775"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s12072-020-10069-3","article-title":"Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study","volume":"14","author":"Poo","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_210","unstructured":"Matsuda, K., and Iwaki, Y. (2014, January 7\u201311). MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (non-alcoholic steatohepatitis) model. Proceedings of the Liver Meeting 2014, Boston, MA, USA."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3748\/wjg.v27.i8.677","article-title":"G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment","volume":"27","author":"Yang","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2019.05.002","article-title":"Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis","volume":"157","author":"Widjaja","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Zai, W., Chen, W., Liu, H., and Ju, D. (2021). Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121912"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Stemmer, S.M., Manojlovic, N.S., Marinca, M.V., Petrov, P., Cherciu, N., Ganea, D., Ciuleanu, T.E., Pusca, I.A., Beg, M.S., and Purcell, W.T. (2021). Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers, 13.","DOI":"10.3390\/cancers13020187"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.3748\/wjg.v23.i23.4146","article-title":"Antioxidant dietary approach in treatment of fatty liver: New insights and updates","volume":"23","author":"Ferramosca","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_216","unstructured":"(2021, December 10). Ionis Pharmaceuticals, Inc.. Available online: https:\/\/www.ionispharma.com\/."},{"key":"ref_217","unstructured":"Lawitz, E., Hassanein, T., Denham, D., Waters, M., Borg, B., Mille, G., Scott, D., Miksztal, A., Culwell, J., and Ellis, D. (2021, January 23\u201326). Efficacy Signals of 4-Week Oral DUR-928 in NASH Subjects. Proceedings of the Digital International Liver Congress 2021, Virtual."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Konuma, K., Itoh, M., Suganami, T., Kanai, S., Nakagawa, N., Sakai, T., Kawano, H., Hara, M., Kojima, S., and Izumi, Y. (2015). Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121528"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/S0168-8278(20)31387-8","article-title":"EDP-297, a novel and potent fxr agonist, exhibit robust antifibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis","volume":"73","author":"Sojoodi","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","article-title":"Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance","volume":"30","author":"Ma","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-Alcoholic Steatohepatitis (NASH)\u2014A Review of a Crowded Clinical Landscape, Driven by a Complex Disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_223","unstructured":"Altimmune, Inc. (2021, December 10). Pemvidutide (ALT-801): Phase 1 12-Week Results. Available online: https:\/\/ir.altimmune.com\/static-files\/d3319658-9809-44ad-a729-05dd6a6bf4c5."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): A randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/apt.14674","article-title":"Randomised clinical trial: A leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease","volume":"47","author":"Chalasani","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"12778","DOI":"10.1038\/s41598-020-69675-8","article-title":"Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease","volume":"10","author":"Simard","year":"2020","journal-title":"Sci Rep"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Puengel, T., De Vos, S., Hundertmark, J., Kohlhepp, M., Guldiken, N., Pujuguet, P., Auberval, M., Marsais, F., Shoji, K.F., and Saniere, L. (2020). The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041140"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10620-020-06280-9","article-title":"G-Protein-Coupled Receptors 120 Agonist III Improves Hepatic Inflammation and ER Stress in Steatohepatitis","volume":"66","author":"Chen","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jhep.2020.02.026","article-title":"Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A","volume":"73","author":"Teng","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/jpet.120.000046","article-title":"The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight","volume":"375","author":"Ookawara","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3904\/kjim.2019.043","article-title":"The utility of ezetimibe therapy in nonalcoholic fatty liver disease","volume":"34","author":"Jun","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"115-LB","DOI":"10.2337\/db20-115-LB","article-title":"Oral Insulin\u2013Induced Reduction in Liver Fat Content in T2DM Patients with Nonalcoholic Steatohepatitis","volume":"69","author":"Kidron","year":"2020","journal-title":"Diabetes"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jcmgh.2018.12.004","article-title":"Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease","volume":"7","author":"Cansby","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.jhepr.2019.100064","article-title":"A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage","volume":"2","author":"Barashi","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_240","unstructured":"(2021, December 10). Pliant Therapeutics. Available online: https:\/\/pliantrx.com\/."},{"key":"ref_241","unstructured":"(2021, December 10). CohBar, Inc.. Available online: https:\/\/www.cohbar.com\/."},{"key":"ref_242","unstructured":"Cerenis Therapeutics (2021, December 10). Results of the Phase I Study of Repeated and Increasing Doses to Assess CER-209 in NASH\/NAFLD: Press Release; 2018. Available online: https:\/\/www.abionyx.com\/images\/pdfs\/images\/pr_cerenis_CER_209_ENG_final_e06d4.pdf."},{"key":"ref_243","unstructured":"(2021, December 10). Hepion Pharmaceuticals. Available online: https:\/\/hepionpharma.com\/."},{"key":"ref_244","unstructured":"(2021, December 10). Lipocine. Available online: https:\/\/www.lipocine.com\/."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1210\/en.2014-1430","article-title":"Osteocalcin protects against non-alcoholic steatohepatitis in a mouse model of metabolic syndrome","volume":"155","author":"Gupte","year":"2020","journal-title":"Endocrinology"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.31229","article-title":"Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights from Systems Biology","volume":"72","author":"Sookoian","year":"2020","journal-title":"Hepatology"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"113888","DOI":"10.1016\/j.addr.2021.113888","article-title":"Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.7150\/ijbs.59588","article-title":"MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"17","author":"Fang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"613213","DOI":"10.3389\/fendo.2021.613213","article-title":"Alternative RNA Splicing in Fatty Liver Disease","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1038\/onc.2013.344","article-title":"Sirtuins in stress response: Guardians of the genome","volume":"33","author":"Vaquero","year":"2014","journal-title":"Oncogene"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/14728222.2020.1743268","article-title":"Sirtuins: Potential therapeutic targets for regulating acute inflammatory response?","volume":"24","author":"Vachharajani","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/01.cco.0000432527.49984.a3","article-title":"Metabolic regulation of Sirtuins upon fasting and the implication for cancer","volume":"25","author":"Zhu","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"HY5","DOI":"10.12659\/MSM.881749","article-title":"SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease","volume":"17","author":"Colak","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"597648","DOI":"10.3389\/fendo.2020.597648","article-title":"Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"de Gregorio, E., Colell, A., Morales, A., and Mar\u00ed, M. (2020). Relevance of SIRT1-NF-\u03baB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113858"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature06261","article-title":"Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes","volume":"450","author":"Milne","year":"2007","journal-title":"Nature"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.3748\/wjg.v22.i46.10084","article-title":"Sirtuins and nonalcoholic fatty liver disease","volume":"22","author":"Nassir","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_258","doi-asserted-by":"crossref","unstructured":"Kundu, A., Dey, P., Park, J.H., Kim, I.S., Kwack, S.J., and Kim, H.S. (2020). EX-527 Prevents the Progression of High-Fat Diet-Induced Hepatic Steatosis and Fibrosis by Upregulating SIRT4 in Zucker Rats. Cells, 9.","DOI":"10.3390\/cells9051101"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/2\/274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:07:55Z","timestamp":1760134075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/2\/274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":258,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["biomedicines10020274"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10020274","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}